Kaneka Eurogentec Expands Capabilities
By Tim Wright, Editor, Contract Pharma | 02.17.21
Receives GMP accreditation for new mRNA manufacturing facility, COVID-19 vaccine production ongoing.
The new facility audited and accredited by Belgian Authorities will allow the production and the purification of up to 10 g scale (up to 1 million doses of vaccine) of RNA for use in human clinical trials and commercial supply, with potential for expansion.
“Manufacturing GMP mRNA complements perfectly our ongoing GMP DNA manufacturing activities providing a one-stop-shop offering Plasmid DNA, linearization and mRNA production,” said Lieven Janssens, president and chief executive officer, Kaneka Eurogentec. “It’s definitely the ambition of Kaneka Eurogentec to become the world leading CDMO for mRNA, as we are already for the production of plasmid DNA.”
The company says two customers have already signed for three mRNA sequences including for early phase COVID-19 clinical trials.